The limitations include how efficient GLP-1 analogues penetrate the blood–brain barrier; how GLP-1 analogues are effectively delivered to the brain; and what concertation of drugs is used to avoid coacting or counteracting with other organs and tissues, etc. More studies need be pursued to find out answers for the clinical treatment in neurodegenerative diseases. This evidence concerns the gene GLP1R and neurodegenerative disease.